Navigation Links
Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
Date:4/7/2008

Unique program continues to advance collaborative research worldwide

HUNTSVILLE, Ala., April 7, 2008 /PRNewswire/ -- Open Biosystems, Inc., announced today that leading research institutions, the Institute for Molecular Bioscience and Diamantina Institute at the University of Queensland, and the Biotech Research and Innovation Centre (BRIC) along with the University of Copenhagen have recently purchased access to Open Biosystems shRNAmir technologies for RNAi by joining the Open Access RNAi(TM) Program.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070423/CLM143LOGO )

Both institutions purchased access to Open Biosystems' lentiviral shRNAmir human and mouse libraries developed in collaboration with Dr. Greg Hannon and Dr. Steve Elledge and exclusively distributed through Open Biosystems.

"Once complete, the Institute for Molecular Bioscience's lentiviral screening facility will be unique in the Southern Hemisphere," Professor John Hancock, Deputy Director (Research) of the IMB, said. "Open Biosystems' Open Access RNAi Program will give all of our research groups access to this valuable genomic screening resource. This will allow our researchers to conduct whole genome or customized gene set knock down experiments that will greatly facilitate discovery in our cell, developmental biology and cancer research programs."

"The lentiviral shRNAmir libraries are important tools for our high throughput genomic facilities," said Professor Kristian Helin, Director of BRIC. "The research groups at University of Copenhagen will now have access to state-of-the art screening facilities to discover novel genes involved in cell-fate decisions and disease."

"We are excited to see worldwide adoption of our Open Access Program. This fuels our ongoing mission to make leading edge technology broadly available in a technically supported and cost-effective way. Lentiviral RNAi screening facilities such as these being developed by our Open Access partners puts genome scale RNAi screening within the reach of all researchers. This will surely accelerate the pace of research and the treatment of human disease," said Troy Moore, Chief Technology Officer at Open Biosystems.

Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, the RNAi Consortium human and mouse lentiviral shRNA libraries as well as RNAi collections targeting Drosophila, C. elegans and Arabidopsis thaliana. Participation in the Open Access RNAi program, provides researchers the most complete and flexible access to their choice of these rapidly evolving RNAi technologies.

About Open Access RNAi

The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company's advanced shRNA libraries, priority technical support, and continued access to all extensions of existing libraries as well as library upgrades. In this manner, Open Biosystems supports academic research without imposing heavy financial burdens on individual labs. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide. Complete details can be found at http://www.openbiosystems.com/OpenAccessRNAi

About Open Biosystems

Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit http://www.openbiosystems.com


'/>"/>
SOURCE Open Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
2. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
3. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
4. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
5. Primera Biosystems Raises $21 Million in Series B Private Round
6. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Study Finds Broadband Access Key to Empowerment of Minority Communities
9. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
10. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
Breaking Biology Technology:
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):